Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Garcia-Carbonero, R; Benavent, M; Jimenez-Fonseca, P; Alonso-Gordoa, T; Teulé, A; Custodio, A; Tafuto, S; La Casta, A; Spada, F; López, C; Ibrahim, T; Iranzo, V; García-Alfonso, P; González-Flores, E; Silva, MJV; Grande, E; Panzuto, F; Crespo, G; Navarro, M; Castellano, D; Hernando, J; Morales-Herrero, R; Alvarez, GI; Soldevilla, B; Capdevila, J.

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)

JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(9): 774-786 [doi:10.1200/JCO-25-01808]

Martín M; Guerrero-Zotano AL; Pérez-López ME; Ruiz-Borrego M; Martinez Jañez N; Chacón JI; Gil-Gil M; Andrés R; Bermejo B; Sánchez-Rovira P; Del Barco S; Ponce JJ; Fernandez I; Martínez de Dueñas E; Hinojo-Gonzále C; González M; García-Garre E; Hernando B; de la Haba-Rodriguez J; Álvarez IM; González-Santiago S; Garcia-Saenz JA; Santaballa A; Casas M; Bezares S; Caballero R; Rojo F; Alba E.

Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

CLINICAL CANCER RESEARCH. 2026; 32(5): 850-858 [doi:10.1158/1078-0432.CCR-25-2435]

Martinez-Lago, N; Cousillas, A; Jara, P; Reboredo, M; Villarroel, PG; Covela, M; Jimeno, R; Agraso, S; Sampedro, P; Carral, A; Perez, M; Garrido, A; Gómez, JD; Alvarez, ND; Fernandez-Montes, A; Lopez, C.

Prognostic impact of clinical factors in MSI-H/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: results from a multicenter real-world study

Esmo Real World Data And Digital Oncology. 2026; 11: [doi:10.1016/j.esmorw.2025.100676]

Fong PC; Kwiatkowski M; Mosca A; Valderrama BP; Li C; Huang YH; Zedan AH; Kuc K; Wiechno P; Laguerre B; Gonzalez-Billalabeitia E; Osipov M; Sener Dede D; Goh JC; Daugaard G; Zhu P; Imai K; Liu Y; Arranz Arija JA.

Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G.

European Urology Focus. 2026; 12(2): 168-173 [doi:10.1016/j.euf.2025.07.018]

van Aken, ESM; O'Cathail, SM; Gandhi, AK; Bussink, J; Castelo-Branco, L; Eriksen, JG; Argilés, G; Hiley, CT; Atkinson, V; Kazmierska, J; Calles, A; Konopa, K; Le Rhun, E; McDonald, F; Mountzios, G; Putora, PM; Muoio, B; Ricardi, U; Westphalen, CB; Wrona, A; Boot, P; Pentheroudakis, G; Belka, C; Lordick, F; Marijnen, CAM; Martins-Branco, D; De Ruysscher, D; Barriuso, J; Devnani, B; de Jong, MC; Prelaj, A.

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Esmo Open. 2026; 11(3): [doi:10.1016/j.esmoop.2026.106076]

Ponz-Sarvisé, M; Rha, SY; Gomez-Roca, CA; Morán, LO; Gill, S; Tortora, G; Geva, R; Saada-Bouzid, E; Santoro, A; Kim, TW; Heudobler, D; Dutcus, CE; Okpara, CE; Ghori, R; Zhang, YW; Vajdi, A; Dettman, EJ; Jin, F; Groisberg, R; Shapira-Frommer, R.

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study

Cancer Research Communications. 2026; 6(3): 673-686 [doi:10.1158/2767-9764.CRC-26-0018]

Beato-Zambrano, C; Nogues, X; Ramírez-Merino, N; Librizzi, MS; Castañeda, S; Foronda, IE; Henao-Carrasco, F; Puente, J; Sotés, IG; Martínez-Díaz-Guerra, G.

Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches

CLINICAL & TRANSLATIONAL ONCOLOGY. 2026; : [doi:10.1007/s12094-026-04256-1]

Poves, MZ; Conesa, MAV; García, MEG; Cánovas, MS; Fernandez, NA; de la Peña, FA; Alcaraz, AC.

Is mortality truly higher for oncology patients admitted to intensive care units? A matched cohort observational study

CLINICAL & TRANSLATIONAL ONCOLOGY. 2026; : [doi:10.1007/s12094-026-04224-9]

Johnston, S; Martin, M; O'Shaughnessy, J; Hegg, R; Tolaney, SM; Guarneri, V; Del Mastro, L; Campone, M; Sohn, J; Boyle, F; Cortes, J; Rugo, HS; Goetz, MP; Hamilton, EP; Huang, CS; Senkus, E; Cicin, I; Testa, L; Neven, P; Huober, J; Shao, Z; Wei, R; Munoz, M; San Antonio, B; Shahir, A; Rastogi, P; Harbeck, N.

Overall survival with abemaciclib in early breast cancer

ANNALS OF ONCOLOGY. 2026; 37(2): 155-165 Nº de citas: 9 [doi:10.1016/j.annonc.2025.10.005]

Molassiotis, A; Jordan, K; Karthaus, M; Dranitsaris, G; Roeland, EJ; Schwartzberg, L; Stimamiglio, V; Alonzi, A; Tilola, SO; Bonizzoni, E; Vázquez, EB; Buchler, T; Cheng, Y; Christoph, DC; Alfonso, PG; Lu, X; Majem, M; Mavroudis, D; Syrigos, K; Tomlins, E; Zhou, Z; Zimovjanová, M; Aapro, M.

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial

ANNALS OF ONCOLOGY. 2026; 37(2): 260-270 Nº de citas: 2 [doi:10.1016/j.annonc.2025.10.017]

Pizarro-Gómez, C; Collado-Borrell, R; Escudero-Vilaplana, V; Massarrah, T; Revuelta-Herrero, JL; Calles, A; Alvarez, R; Villanueva-Bueno, C; Mur-Mur, A; Sánchez-Fresneda, MN; Herranz, A; Benedí-González, J; Martín, M; Sanjurjo, M.

Economic impact of lung cancer clinical trials: Assessing cost savings in medication and testing

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2026; : [doi:10.1177/10781552251409387]

Rosa, AA; Carolina, AP; Marta, AV; Francisco, A; Adriana, FG; Natalia, G; Pablo, LL; Cristina, MF; Lydia, MS; Ulrike, N; Marina, S; Guillermo, HT; Henar, CG; Ana, GOD.

Experience of a Referral Center with Desmoid Tumors, Part 2: A Retrospective Analysis of 109 Cases

Cancers. 2026; 18(2): [doi:10.3390/cancers18020305]

López-Tarruella, S; Guerrero-Zotano, A; Antolín, S; Cruz, J; Martínez, P; Rodríguez, CA; Falo, C; Rodríguez-Lescure, A; Adrover, E; Hernández, M; Andrés, R; Chacón, JI; Romero, JLA; Miguel, A; Gómez-Raposo, C; Margelí, M; González, I; Guerra, JA; Antón, A; Tibau, A; Miralles, JJ; Escudero, MJ; Bezares, S; Rojo, F; Alvarez, I.

Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)

Therapeutic Advances in Medical Oncology. 2026; 18: [doi:10.1177/17588359261421813]

de Andrea, CE; Abengozar-Muela, M; Arranz, JA; Climent, MA; Puente, J; Vizcay, A; de la Fuente, LM; Jurado, JM; Bonfill, T; Santander, C; Villa, JC; Pujol, E; Rosero, AC; Gomez, J; Fernández, EM; Fernández, CA; Ramirez, I; Arnáiz, P; López-Janeiro, A; Melero, I; Sanmamed, MF; Pérez-Gracia, JL.

Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients

OncoImmunology. 2025; 14(1): Nº de citas: 1 [doi:10.1080/2162402X.2025.2538687]

Cerezuela-Fuentes, P; Piñero-Madrona, A; Muñoz-Couselo, E; Manzano, JL; Berciano-Guerrero, MA; Majem, M; Espinosa, E; Soria, A; de Miguel, PA; Castaño, AG; Crespo, G; Sanz, LG; de la Rosa, CA; Fernández-Morales, LA; Puértolas, T; Rodríguez, JF; de la Borbolla, MR; Bellido, L; Castro, RL; Pérez, VN; Arroyo, FRG; Guzmán, JCV; Balea, BC; Hernández, B; Algarra, SM; Márquez-Rodas, I.

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04164-w]

Lopez-Jiménez, C; de Lucas, MB; de la Tabla, AGO; Alonso, NG; Arregui, M; Alvarez, R.

Primary Cardiac Sarcomas: Clinical Characteristics, Management, and Outcomes at a Spanish National Reference Center

Cancers. 2025; 17(24): [doi:10.3390/cancers17243947]

Jara, P; Ariant, M; Jiménez, R; Bringas, M; Herrero, B; Echavarría, I; Jerez, Y; Lopez-Tarruella, S; Márquez-Rodas, I; del Monte-Millán, M; Massarrah, T; de la Peña, FA; Martín, M.

Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2-advanced breast cancer after CDK4/6 inhibitor

BREAST CANCER RESEARCH AND TREATMENT. 2025; 215(1): Nº de citas: 1 [doi:10.1007/s10549-025-07873-6]

Salazar, J; Arranz, MJ; Martin-Broto, J; Serra, M; Palmerini, E; Martínez-García, J; Juan-Ribelles, A; Andion, M; Martinez-Trufero, J; Gutiérrez, G; Echebarria-Barona, A; Vaz-Salgado, MA; Regueiro, A; Alvarez, R; Valverde, C; Luna, P; Blay, P; Sebio, A.

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol

Pharmaceuticals. 2025; 18(12): [doi:10.3390/ph18121855]